首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Urologic oncology-seminars and original investigations

缩写:UROL ONCOL-SEMIN ORI

ISSN:1078-1439

e-ISSN:1873-2496

IF/分区:2.8/Q2

文章目录 更多期刊信息

共收录本刊相关文章索引4576条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Jiafu Lu,Bo Luo,Chao Xue et al. Jiafu Lu et al.
Background: Renal cell carcinoma (RCC) exhibits substantial clinical heterogeneity, and conventional clinicopathological models have limited ability to provide precise individualized risk stratification. Circulating kidne...
Mohammad Reza Nowroozi,Mohammad Hamidi Madani,Amirreza Farzin et al. Mohammad Reza Nowroozi et al.
Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard of care for muscle-invasive bladder cancer (MIBC), yet treatment response is highly variable and current clinical predictors are inadequate. Deep learning (DL) of...
Joseph McGrath,Robert Willis,Sudharshanan Balaji et al. Joseph McGrath et al.
Lutetium-177-labeled prostate-specific membrane antigen radioligand therapy (¹⁷⁷Lu-PSMA-RLT) emerged as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC) following FDA approval in 2022. Its role in metastatic ...
Takafumi Yanagisawa,Kosuke Iwatani,Fumihiko Urabe et al. Takafumi Yanagisawa et al.
Background: Enfortumab vedotin plus pembrolizumab (EVP) has emerged as a standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). However, large-scale real-world data in Japanese pat...
Charles B Nguyen,Zachery R Reichert Charles B Nguyen
Despite recent advances in therapies, metastatic castration-resistant prostate cancer (mCRPC) remains incurable with poor prognosis in which novel, more effective treatments are urgently needed. Antibody-drug conjugates (ADCs) are a novel c...
Cem Onal,Gurcan Erbay,Ozan Cem Guler et al. Cem Onal et al.
Background: Diffusion-weighted magnetic resonance imaging (MRI)-derived apparent diffusion coefficient (ADC) has been investigated as a biomarker in prostate cancer, yet its prognostic relevance after definitive radiother...
Xueping Liu,Kui Fu,Lixia Xiong et al. Xueping Liu et al.
Objective: To investigate the clinicopathological features, immunophenotype, treatment response, and prognosis of plasmacytoid urothelial carcinoma (PUC) of the bladder, and to provide evidence for clinical management. ...
Joseph McGrath,Indraneel Banerjee,Yudai Ishiyama et al. Joseph McGrath et al.
Purpose: Bacillus Calmette-Guérin (BCG) remains the standard first-line therapy for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC), yet recurrence and progression remain clinically significant. Multiple ...
Hidetsugu Takahashi,Wataru Fukuokaya,Takafumi Yanagisawa et al. Hidetsugu Takahashi et al.
Background: Immune checkpoint inhibitor (ICI)-based combination therapy (ICI plus ICI [IO-IO] or ICI plus tyrosine kinase inhibitor [IO-TKI]) is the standard first-line treatment for metastatic renal cell carcinoma (mRCC)...